Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas.

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content

Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer

Understanding 6‑Month CDP in MS: An Overview with Dr. Barry Singer

Understanding PIRA in MS: An Overview with Dr. Barry Singer

IL-4, IL-13, AND IL-5 ARE DRIVERS OF SYSTEMIC TYPE 2 INFLAMMATION

Eosinophilic inflammation has multiple drivers1,2

The pathophysiology of ITP stems from complex immune dysregulation drives thrombocytopenia and inflammation

Rilzabrutinib a BTK inhibitor

Complex immune dysregulation impact on QoL

Interplay between the innate and adaptive immunity

Charting New Course: The Frontier of Early Intervention and Disease Modification in AD

Early Intervention and Disease Modification in Atopic Dermatitis

Early Detection and Intervention

Early identification of autoantibodies can help predict T1D development before symptoms appear.

Stages of Type 1 Diabetes and DKA Impact

Type 1 diabetes progresses from presymptomatic autoimmunity to symptomatic hyperglycemia, ultimately requiring lifelong insulin therapy. DKA can cause severe metabolic imbalances requiring hospitalization, significantly disrupting daily life and posing serious health risks.